ReWalk Robotics, doing business as Lifeward, announced that Jeff Dykan, current chairman of the board of directors, will retire from his role and will not stand for reelection at the 2024 meeting of shareholders. Joseph Turk, who has served on Lifeward’s board since 2022, has been appointed as the incoming chairman and will assume the role following the shareholder meeting.
Under Dykan’s leadership, Lifeward grew from an early-stage concept, attracted a management team to lead development, navigated regulatory clearances including a De Novo approval with the Food and Drug Administration, conducted an initial public offering, established an exoskeleton coverage policy with the Veterans Affairs, acquired AlterG, and most recently, established reimbursement for personal exoskeletons under Medicare. “Lifeward is greatly appreciative of Mr. Dykan’s guidance and leadership throughout the company’s history of pioneering the exoskeleton and physical rehabilitation industries,” it said.
“Lifeward has benefitted greatly from Jeff’s leadership as he guided the company’s growth from an initial concept into the commercial business it is today,” said Turk. “Thanks to Jeff’s efforts in establishing this company—and this industry—we are now able to shift our focus toward commercial expansion and market development across both our ReWalk and AlterG product lines. We wish Jeff all the best as he steps down from his current role and extend our sincere gratitude for all his years of service.”
